An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Standard
An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers. / Madorsky-Feldman, Dana; Sklair-Levy, Miri; Perri, Tamar; Laitman, Yael; Paluch-Shimon, Shani; Schmutzler, Rita; Rhiem, Kerstin; Lester, Jenny; Karlan, Beth Y; Singer, Christian F; Van Maerken, Tom; Claes, Kathleen; Brunet, Joan; Izquierdo, Angel; Teulé, Alex; Lee, Jong Won; Kim, Sung-Won; Arun, Banu; Jakubowska, Anna; Lubinski, Jan; Tucker, Katherine; Poplawski, Nicola K; Varesco, Liliana; Bonelli, Luigina Ada; Buys, Saundra S; Mitchell, Gillian; Tischkowitz, Marc; Gerdes, Anne-Marie; Seynaeve, Caroline; Robson, Mark; Kwong, Ava; Tung, Nadine; Tessa, Nalven; Domchek, Susan M; Godwin, Andrew K; Rantala, Johanna; Arver, Brita; Friedman, Eitan.
I: Breast Cancer Research and Treatment, Bind 157, Nr. 2, 06.2016, s. 319-327.Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Harvard
APA
Vancouver
Author
Bibtex
}
RIS
TY - JOUR
T1 - An international survey of surveillance schemes for unaffected BRCA1 and BRCA2 mutation carriers
AU - Madorsky-Feldman, Dana
AU - Sklair-Levy, Miri
AU - Perri, Tamar
AU - Laitman, Yael
AU - Paluch-Shimon, Shani
AU - Schmutzler, Rita
AU - Rhiem, Kerstin
AU - Lester, Jenny
AU - Karlan, Beth Y
AU - Singer, Christian F
AU - Van Maerken, Tom
AU - Claes, Kathleen
AU - Brunet, Joan
AU - Izquierdo, Angel
AU - Teulé, Alex
AU - Lee, Jong Won
AU - Kim, Sung-Won
AU - Arun, Banu
AU - Jakubowska, Anna
AU - Lubinski, Jan
AU - Tucker, Katherine
AU - Poplawski, Nicola K
AU - Varesco, Liliana
AU - Bonelli, Luigina Ada
AU - Buys, Saundra S
AU - Mitchell, Gillian
AU - Tischkowitz, Marc
AU - Gerdes, Anne-Marie
AU - Seynaeve, Caroline
AU - Robson, Mark
AU - Kwong, Ava
AU - Tung, Nadine
AU - Tessa, Nalven
AU - Domchek, Susan M
AU - Godwin, Andrew K
AU - Rantala, Johanna
AU - Arver, Brita
AU - Friedman, Eitan
PY - 2016/6
Y1 - 2016/6
N2 - Female BRCA1/BRCA2 mutation carriers are at substantially increased risk for developing breast and/or ovarian cancer, and are offered enhanced surveillance including screening from a young age and risk-reducing surgery (RRS)-mastectomy (RRM) and/or salpingo-oophorectomy (RRSO). While there are established guidelines for early detection of breast cancer in high-risk women who have not undergone RRM, there are less developed guidelines after RRM. We evaluated the schemes offered before and after RRS in internationally diverse high-risk clinics. An e-mailed survey was distributed to high-risk clinics affiliated with CIMBA. Overall, 22 centers from 16 countries responded. Pre RRS surveillance schemes overwhelmingly included breast imaging (primarily MRI) from 18 to 30 years and clinical breast exam (CBE) at 6-12 month intervals. For ovarian cancer, all but 6 centers offered semiannual/annual gynecological exam, transvaginal ultrasound, and CA 125 measurements. Post RRM, most centers offered only annual CBE while 4 centers offered annual MRI, primarily for substantial residual breast tissue. After RRSO only 4 centers offered specific gynecological surveillance. Existing guidelines for breast/ovarian cancer detection in BRCA carriers are being applied pre RRS but are not globally harmonized, and most centers offer no specific surveillance post RRS. From this comprehensive multinational study it is clear that evidence-based, long-term prospective data on the most effective scheme for BRCA carriers post RRS is needed.
AB - Female BRCA1/BRCA2 mutation carriers are at substantially increased risk for developing breast and/or ovarian cancer, and are offered enhanced surveillance including screening from a young age and risk-reducing surgery (RRS)-mastectomy (RRM) and/or salpingo-oophorectomy (RRSO). While there are established guidelines for early detection of breast cancer in high-risk women who have not undergone RRM, there are less developed guidelines after RRM. We evaluated the schemes offered before and after RRS in internationally diverse high-risk clinics. An e-mailed survey was distributed to high-risk clinics affiliated with CIMBA. Overall, 22 centers from 16 countries responded. Pre RRS surveillance schemes overwhelmingly included breast imaging (primarily MRI) from 18 to 30 years and clinical breast exam (CBE) at 6-12 month intervals. For ovarian cancer, all but 6 centers offered semiannual/annual gynecological exam, transvaginal ultrasound, and CA 125 measurements. Post RRM, most centers offered only annual CBE while 4 centers offered annual MRI, primarily for substantial residual breast tissue. After RRSO only 4 centers offered specific gynecological surveillance. Existing guidelines for breast/ovarian cancer detection in BRCA carriers are being applied pre RRS but are not globally harmonized, and most centers offer no specific surveillance post RRS. From this comprehensive multinational study it is clear that evidence-based, long-term prospective data on the most effective scheme for BRCA carriers post RRS is needed.
U2 - 10.1007/s10549-016-3805-0
DO - 10.1007/s10549-016-3805-0
M3 - Journal article
C2 - 27117159
VL - 157
SP - 319
EP - 327
JO - Breast Cancer Research and Treatment
JF - Breast Cancer Research and Treatment
SN - 0167-6806
IS - 2
ER -
ID: 174183608